JNJ — JOHNSON & JOHNSON
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 200406 ·
Last close
$264.74
Market Cap
$638.00B
52W High
$281.07
52W Low
$178.91
ADV30
6,364,541
Next earnings
2026-10-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 24,062,000,000 | 15,956,000,000 | 6,395,000,000 | 5,235,000,000 | 200,894,000,000 | 21,688,000,000 | 119,708,000,000 |
| Dec 2025 | 24,564,000,000 | 16,596,000,000 | 5,591,000,000 | 5,116,000,000 | 199,210,000,000 | 19,709,000,000 | 117,666,000,000 |
| Sep 2025 | 23,993,000,000 | 16,690,000,000 | 7,096,000,000 | 5,152,000,000 | 192,816,000,000 | 18,231,000,000 | 113,539,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$27,608,000,000
Investing CF
$-7,177,000,000
Financing CF
$-18,543,000,000
CapEx
$-5,380,000,000
Dividends Paid
$-12,621,000,000
Buybacks
$-8,075,000,000
EPS Diluted TTM
$8.63
As of
2026-07-26
Balance + Analyst (yfinance extras)
Retained Earnings
—
Inventory
$15,144,000,000
Receivables
$19,046,000,000
ST Investments
$336,000,000
EBIT TTM
$26,208,000,000
Pretax Income TTM
$25,196,000,000
Interest Exp TTM
$1,012,000,000
Analysts
22
Yahoo Snapshot (yfinance, live)
Total Revenue
$97,929,003,008
EBITDA
$34,872,000,512
Free Cash Flow
$16,885,125,120
Enterprise Value
$668,298,838,016
Total Cash
$20,757,999,616
Total Debt
$49,036,001,280
Shares Out
2,409,898,597
Trailing EPS
$8.63
Book Value
$35.28
ROE
25.7%
ROA
8.6%
Div Yield
2.02%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 94,193,000,000 | 25,596,000,000 | 26,804,000,000 | 199,210,000,000 | 117,666,000,000 | 81,544,000,000 | 24,530,000,000 |
| Dec 2024 | 88,821,000,000 | 21,249,000,000 | 14,066,000,000 | 180,104,000,000 | 108,614,000,000 | 71,490,000,000 | 24,266,000,000 |
| Dec 2023 | 85,159,000,000 | 22,009,000,000 | 35,153,000,000 | 167,558,000,000 | 98,784,000,000 | 68,774,000,000 | 22,791,000,000 |
| Dec 2022 | 79,990,000,000 | 21,013,000,000 | 17,941,000,000 | 187,378,000,000 | 110,574,000,000 | 76,804,000,000 | 21,194,000,000 |
TTM Snapshot
Revenues TTM
$85,711,000,000
NetIncome TTM
$44,179,000,000
OpCashFlow TTM
$0
Assets (Latest)
$199,210,000,000
Forward EPS
$12.45
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ABBV | AbbVie Inc. | $462.26B | $261.59 | — |
| LLY | ELI LILLY & Co | $1.03T | $1157.08 | — |
| MRK | Merck & Co., Inc. | $358.50B | $145.31 | — |
| NVS | NOVARTIS AG | $270.98B | $142.57 | — |
| NVSEF | NOVARTIS AG | $267.87B | $140.93 | — |
News headlines (Yahoo Finance, 1h cache)
What is Johnson & Johnson’s (JNJ) Economic Moat, and is it Widening or Narrowing?
2026-10-01 00:12 · Yahoo
3 Reasons Johnson & Johnson Is Still a Buy With Its Stock Near a Record High
2026-09-30 19:20 · Yahoo
Was The Run In JNJ Stock Hiding In Plain Sight?
2026-09-30 19:01 · Yahoo
Microsoft vs. Johnson & Johnson: Which Dividend Will Pay You More in 10 Years?
2026-09-30 15:30 · Yahoo
BofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline Strength
2026-09-30 11:15 · Yahoo
Johnson & Johnson (JNJ) Shares In Focus After New Adolescent gMG Data
2026-09-30 01:10 · Yahoo
Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know
2026-09-29 20:45 · Yahoo
Muse AI Agent Stock Portfolio: 2 Non-AI Stock Picks You Should Not Miss
2026-09-29 19:18 · Yahoo
Johnson & Johnson's psoriasis drug Icotyde could hit $4.5B in peak sales, BofA says
2026-09-29 18:42 · Yahoo
Retinitis Pigmentosa Market Outlook to Strengthen During the Forecast Period (2026-2036) with Growing Focus on Disease-Modifying Therapies | DelveInsight
2026-09-29 14:31 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.